Core Insights - Aptose Biosciences Inc. presented data from its Phase 1/2 TUSCANY trial for newly diagnosed AML patients treated with tuspetinib in combination with venetoclax and azacitidine at the EHA 2025 Congress [1][3] Group 1: Study Overview - The TUS+VEN+AZA triplet is being developed as a mutation-agnostic frontline therapy for newly diagnosed AML patients who cannot receive induction chemotherapy [2][8] - The TUSCANY trial is designed to test various doses of tuspetinib in combination with standard dosing of azacitidine and venetoclax [9] Group 2: Key Findings - The addition of tuspetinib to standard care creates a well-tolerated and mutation-agnostic frontline therapy for newly diagnosed AML [5] - Ten AML patients have been treated with the TUS+VEN+AZA combination, with complete remissions and minimal residual disease negativity observed across diverse mutations [6][7] - At the 40 mg dose level, three out of four patients achieved complete remissions and were MRD-negative, while at the 80 mg dose level, all three patients achieved composite complete remissions [6] Group 3: Safety and Efficacy - No dose-limiting toxicities (DLTs) have been observed to date, and all ten subjects treated remain alive [6][7] - TUS demonstrated activity across diverse genetic populations, including those with adverse TP53 mutations [6][8] - The triplet therapy continues to be well tolerated, with no treatment-related deaths or significant adverse events reported [6][7]

Core Viewpoint - Aptose Biosciences Inc. is advancing its clinical-stage precision oncology therapy, tuspetinib (TUS), in a Phase 1/2 trial (TUSCANY) for newly diagnosed acute myeloid leukemia (AML) patients, with recent approval to escalate dosing based on positive safety and efficacy data [1][2][3]. Group 1: Clinical Trial Progress - The Cohort Safety Review Committee has approved the escalation of the TUS dose from 80 mg to 120 mg due to favorable safety and efficacy data [1][3]. - The first patient has been dosed at the 120 mg level, and enrollment for this cohort is ongoing [1][7]. - No significant safety concerns or dose-limiting toxicities have been reported in the trial, including no prolonged myelosuppression in subjects [2][7]. Group 2: Efficacy and Safety Data - Data from the initial cohorts (40 mg and 80 mg) show promising clinical safety and antileukemic activity, even in difficult-to-treat AML populations [3][4]. - The TUS+VEN+AZA triplet therapy has achieved complete remissions (CRs) and minimal residual disease (MRD) negativity with favorable safety profiles [7]. Group 3: Future Presentations and Data - Updated data will be presented at the European Hematology Association Congress (EHA 2025) in Milan, Italy, including safety, CRs, MRD, and pharmacokinetic findings [2][4]. - The TUSCANY trial is being conducted at 10 leading U.S. clinical sites, with an anticipated enrollment of 18-24 patients by mid-late 2025 [5].

Core Insights - Aptose Biosciences Inc. announced that data from its Phase 1/2 TUSCANY trial will be presented at the European Hematology Association Congress in June 2025, focusing on the TUS+VEN+AZA triplet therapy for newly diagnosed AML patients [1][2] Group 1: TUSCANY Trial Overview - The TUS+VEN+AZA triplet is being developed as a safe and mutation-agnostic frontline therapy for newly diagnosed AML patients who cannot receive induction chemotherapy [2][4] - Initial dose cohorts of the TUS+VEN+AZA triplet have shown safety, complete remissions, and minimal residual disease (MRD) negativity across diverse mutation profiles, including TP53 and FLT3 [2][4] - The TUSCANY trial is being conducted at 10 leading U.S. clinical sites, with an expected enrollment of 18-24 patients by mid to late 2025 [5] Group 2: Presentation Details - The oral presentation at EHA will include updated safety data, complete remission rates, and MRD findings, along with longer follow-up duration [2][3] - The presentation is scheduled for June 12, 2025, and will be led by Dr. Gabriel Mannis from Stanford University [3] Group 3: Company Background - Aptose Biosciences is focused on developing precision medicines for unmet medical needs in oncology, particularly in hematology [7] - The lead clinical-stage oral kinase inhibitor, tuspetinib (TUS), has shown activity as both a monotherapy and in combination therapy for relapsed or refractory AML [7]

Core Insights - Aptose Biosciences is advancing its TUSCANY clinical trial of tuspetinib in combination with venetoclax and azacitidine for newly diagnosed acute myeloid leukemia (AML), showing promising safety and efficacy data [2][3][4] - The company reported a net loss of $5.5 million for Q1 2025, a decrease from $9.6 million in Q1 2024, indicating improved financial performance [8][14] - Aptose's common shares are now listed on the OTC Markets under the ticker "APTOF," enhancing accessibility for U.S. investors [4] Clinical Trial Progress - The TUSCANY trial has shown that patients receiving both 40 mg and 80 mg doses of tuspetinib achieved complete remissions, with no safety concerns reported [2][3][4] - In the first cohort, three patients on the 40 mg dose achieved complete remissions, while in the second cohort, all three patients on the 80 mg dose also achieved complete remissions [3][4] - The trial aims to create a mutation-agnostic triplet frontline therapy for AML patients, including those without FLT3 mutations [3] Financial Performance - Research and development expenses decreased to $2.3 million in Q1 2025 from $6.4 million in Q1 2024, primarily due to reduced clinical trial activities and lower personnel costs [8][12][15] - The company reported total cash, cash equivalents, and restricted cash of $4.7 million as of March 31, 2025, with expectations to fund operations until the end of May 2025 [14] - The net loss per share for Q1 2025 was $2.61, compared to $22.02 in Q1 2024, reflecting a significant reduction in losses [8] Corporate Developments - Aptose is preparing for upcoming milestones, including reporting maturing data from the TUSCANY trial at the European Hematology Association (EHA) meeting and the American Society of Hematology (ASH) conference [5][6][11] - The company has implemented financing and cost reduction efforts to extend its cash runway, indicating proactive management of financial resources [14]

Core Insights - Aptose Biosciences is developing a unique triple drug therapy (TUS+VEN+AZA) for newly diagnosed acute myeloid leukemia (AML) patients, aiming for a safe and mutation-agnostic frontline treatment [1][6] - Initial data from the Phase 1/2 TUSCANY trial shows promising safety and efficacy, with complete remissions and measurable residual disease (MRD) negativity observed in patients with diverse mutations [1][4] Group 1: Clinical Trial Details - The TUSCANY trial has initiated dosing with tuspetinib (TUS) at 40 mg and 80 mg in combination with venetoclax (VEN) and azacitidine (AZA), demonstrating safety and antileukemic activity [2][4] - The trial is designed to evaluate various doses and schedules of TUS for AML patients who cannot receive induction chemotherapy, with a target enrollment of 18-24 patients by mid-late 2025 [7] Group 2: Patient Outcomes - In the first cohort, a patient with biallelic TP53 mutations achieved complete remission and MRD-negative status, while another FLT3-wildtype patient also achieved complete remission [4] - In the second cohort receiving 80 mg of TUS, all three patients showed blast reductions meeting criteria for complete remissions or complete remission with incomplete blood count recovery (CRi) [4] Group 3: Company Overview - Aptose Biosciences focuses on developing precision medicines for oncology, with tuspetinib as a lead candidate showing activity in relapsed or refractory AML and being advanced as a frontline therapy [9]

Core Viewpoint - Aptose Biosciences Inc. announced that KPMG LLP will not stand for re-appointment as the independent registered public accounting firm for the 2025 annual audit, while KPMG will continue to review the company's quarterly interim financial results through the first two fiscal quarters of 2025 [1]. Group 1: Company Announcement - KPMG did not seek the company's consent regarding its decision not to stand for re-appointment, and neither the Board of Directors nor the Audit Committee participated in this decision [2]. - KPMG issued unqualified reports on the company's consolidated financial statements for the fiscal years ended December 31, 2024, and 2023 [3]. - There were no disagreements or reportable events between the company and KPMG during the fiscal years ended December 31, 2024, and 2023, except for a communicated material weakness in internal control over financial reporting related to complex financial instruments [4]. Group 2: Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [6]. - The company's lead compound, tuspetinib (TUS), is an oral kinase inhibitor being developed as a frontline triplet therapy for newly diagnosed acute myeloid leukemia (AML) [6].

Core Viewpoint - Aptose Biosciences Inc. is participating in the 2025 Bloom Burton & Co. Healthcare Investor Conference to present its developments in precision oncology, specifically focusing on its lead compound tuspetinib for treating acute myeloid leukemia [1][4]. Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, with an emphasis on hematology [5]. - The company's lead product, tuspetinib (TUS), is an oral kinase inhibitor that has shown efficacy as both a monotherapy and in combination therapy for relapsed or refractory acute myeloid leukemia (AML) [5]. - Tuspetinib is being developed as a frontline triplet therapy for newly diagnosed AML patients [5]. Conference Details - The 2025 Bloom Burton & Co. Healthcare Investor Conference will take place on May 5-6, 2025, in Toronto [1][4]. - Dr. William G. Rice, Chairman, President, and CEO of Aptose, will present on May 5, 2025, at 3:00 p.m. EDT [2][3]. - The presentation will be available via webcast, and further details can be found on the Aptose website [3]. Investor Engagement - The conference provides an opportunity for investors to receive corporate updates from various Canadian healthcare companies through presentations and one-on-one meetings [4]. - Aptose is open to scheduling one-on-one meetings with interested investors during the conference [2].

Core Insights - Aptose Biosciences Inc. is a clinical-stage precision oncology company focused on developing tuspetinib (TUS) as a frontline therapy for newly diagnosed acute myeloid leukemia (AML) [1][5] - The company will participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference in Toronto on May 5-6, 2025, where Dr. William G. Rice will present and host one-on-one meetings [1][2][4] Company Overview - Aptose is committed to developing precision medicines to address unmet medical needs in oncology, with a focus on hematology [5] - The company's pipeline includes small molecule cancer therapeutics designed for single-agent efficacy and to enhance the efficacy of other anti-cancer therapies without overlapping toxicities [5] - Tuspetinib (TUS) is an oral kinase inhibitor that has shown activity as both a monotherapy and in combination therapy for patients with relapsed or refractory AML, and is being developed as a triplet therapy for newly diagnosed AML [5] Conference Details - The 2025 Bloom Burton & Co. Healthcare Investor Conference will feature corporate updates from various Canadian healthcare companies, providing opportunities for investors to engage with company representatives [4] - Dr. William G. Rice's corporate presentation is scheduled for May 5, 2025, at 3:00 p.m. EDT, and will be available via webcast [3]

Core Viewpoint - Aptose Biosciences Inc. has been determined by the Nasdaq Hearings Panel to delist its common shares from Nasdaq due to non-compliance with the Exchange's equity requirement by the deadline of March 31, 2025 [1] Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [3] - The company's lead compound, tuspetinib (TUS), is an oral kinase inhibitor aimed at treating acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy for newly diagnosed AML patients [3] Delisting Details - The Nasdaq Hearings Panel's decision was based on Aptose's failure to demonstrate compliance with the equity requirement outlined in Listing Rule 5550(b)(1) by the specified date [1] - Trading of Aptose's common shares will be suspended effective April 2, 2025, following the Panel's determination [1] Future Plans - The company and its board are considering all available options, including an appeal against the delisting decision, while continuing to execute its business plan [2] - Aptose intends to seek a listing on a U.S. national Securities Exchange at an appropriate time [2]